Hold JNJ at $269; deploy tiered entries at $275 breakout or $260-265 pullback with $253 stop
Three-way analyst convergence on Hold is the binding signal. The aggressive, conservative, and neutral analysts all reach Hold directionally — only magnitude and execution differ. Structural floor (200 SMA at $236, AAA credit, 62-year dividend streak, $17B+ FCF) is fully intact. The $269 core position is maintained with explicit tiered entry architecture and alpha-budget decay tracking; this is active contingent management, not passive inaction. Q3 earnings is the only calendar catalyst that resolves whether the embedded 41% forward EPS expansion ($8.62→$12.14) materializes to justify the 31x trailing P/E. Re-rating requires either momentum-confirmed upside ($275 breakout) or the pullback entry ($260-265) providing better risk-adjusted entry.
| Position | Action |
|---|---|
| Confirmed close above $275 with positive MACD histogram cross | Add Tier 1 (50% of target new capital) |
| Pullback to $260-265 with 50 SMA holding | Add Tier 2 (remaining 50% of target new capital) |
| Core position maintenance | Do not add until technical confirmation arrives |
JNJ's forward P/E of 22.18x is justified by de-risked EPS expansion to $12.14 (40% growth), with Caplyta's Phase 3 Bipolar I Mania win validating the $14.6B acquisition and ICOTYDE providing a first-in-class STELARA replacement, all while Q2 2026 revenue accelerated 6.6% YoY to $25.31B in a macro environment (higher-for-longer, 8% recession odds) that rewards defensive, cash-generative quality names.
| Indicator | Value | Signal |
|---|---|---|
| Price | $269.19 | neutral |
| 10 EMA | $268.93 | neutral |
| 50 SMA | $263.00 | bullish |
| 200 SMA | $237.19 | bullish |
| RSI (14) | 53.69 | neutral |
| MACD Line | 1.51 | bearish |
| MACD Signal Line | 2.06 | bearish |
| MACD Histogram | -0.55 | bearish |
| Bollinger Upper Band | $276.69 | neutral |
| Bollinger Middle Band | $269.53 | neutral |
| Bollinger Lower Band |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to $260-265 with 50 SMA holding and volume ≥7M
Then: Deploy remaining 50% of target new capital
↩ rebuts: “Acquisition was an unproven synergy promise”
EV: +8–10% to $278–$285 · concedes: Trailing P/E of 31.23x is elevated versus historical; Short-term MACD momentum has cooled; Stock up ~58% over twelve months; Recent consolidation is only 3 weeks old
JNJ's "Quality at Any Price" narrative is the wrong setup right now — the right move is to stop buying and let the multiple reset. At $269 with a 31x trailing P/E after a 58% run, near a technical breakdown, ahead of a Q3 earnings print with negative skew, in a macro regime that compresses long-duration multiples, the risk/reward is asymmetric to the downside.
· concedes: JNJ's quality, balance sheet, and dividend protect against a collapse; JNN will likely be a $300+ stock within two years on pipeline execution strength; The franchise deserves respect; Quality means waiting for the right entry — not buying at any price; The bull isn't fighting the tape, he's fighting the math — and so is the bear
→ vs conservative: PEG ratio of 2.83 comparison to steady-state growers is apples to oranges; using July $252 anchor creates anchoring trap that will miss the entire forward catalyst move
→ vs conservative: Staged entry targeting 6-8% pullback to $252-$258 on a stock 13.5% above 200 SMA has only 30% probability of success; by then Caplyta expansion, ICOTYDE ramp, Orthopedics deal, and Q3 earnings will have already fired
→ vs neutral: Calling JNJ a textbook defensive beneficiary and then recommending Hold for dividends is a half-measure; the macro setup argues for leaning in, not passive waiting
| $262.38 |
| neutral |
| ATR | $5.23 | neutral |
| VWMA | $270.13 | bearish |
| 50-day Trend | Up | bullish |
| 200-day Trend | Up | bullish |
Support: 262.38 · 263 · 260.79 | Resistance: 276.69 · 275.21 · 278.43
JNJ shows a mixed technical picture: the long-term trend remains firmly bullish with price well above the rising 200 SMA ($237.19) and no structural damage, but short-term momentum has turned cautious following a MACD bearish crossover. RSI at 53.69 is neutral (not oversold), suggesting limited capitulation and room for either direction. The stock is consolidating in a $263–$278 range, with the 50 SMA ($263.00) acting as near-term support and the upper Bollinger Band ($276.69) as resistance. ATR of $5.23 indicates moderate volatility, appropriate for stop-loss placement 1.5–2x ATR below entry. The overall bias remains bullish for long-term holders, with a recommendation to HOLD; new entries should await either a pullback to the $263–$266 support zone or a confirmed breakout above $278 with volume.
Market Cap
$648.7B
Beta
0.235
Dividend Yield
1.99%
Trailing P/E
31.23x
Forward P/E
22.18x
PEG Ratio
2.83
P/B
7.63x
EPS (TTM)
$8.62
Forward EPS
$12.14
52-Week Range
$174.83–$281.07
50-DMA
$263.54
200-DMA
$238.98
Revenue (TTM)
$97.93B
Gross Profit (TTM)
$66.73B
Net Income (TTM)
$21.04B
Gross Margin (TTM)
68.1%
Operating Margin (TTM)
29.2%
Profit Margin (TTM)
21.5%
ROE
25.7%
ROA
8.6%
Q2 2026 Revenue
$25.31B
Q2 2026 Gross Profit
$17.26B
Q2 2026 Operating Income
$7.17B
Q2 2026 Net Income
$5.53B
Q2 2026 Diluted EPS
$2.27
Q2 2026 Gross Margin
68.2%
Q2 2026 Operating Margin
28.3%
Q2 2026 Total Assets
$201.1B
Q2 2026 Stockholders' Equity
$84.97B
Q2 2026 Total Debt
$49.04B
Q2 2026 Net Debt
$28.61B
Q2 2026 Cash & Equivalents
$20.42B
Q2 2026 Working Capital
$4.88B
Q2 2026 Current Ratio
1.089
Q2 2026 Operating Cash Flow
$8.62B
Q2 2026 CapEx
$1.32B
Q2 2026 Free Cash Flow
$7.30B
Q2 2026 Dividends Paid
$3.23B
Q2 2026 Share Buybacks
$0.22B
Annualized FCF (TTM)
$16.9B
Annualized Dividend Obligation
~$12.6B
Quarterly Dividend
~$1.30/share
Intra-Cellular (Caplyta) Acquisition
$14.6B
Goodwill + Intangibles
$96.7B
Tangible Book Value
-$11.7B
Composite Quality Score
~8.0
Strengths
Concerns
The report assesses Johnson & Johnson as a premium-quality defensive healthcare compounder with best-in-class 68% gross margins and $16.9B annual FCF, trading at a premium trailing P/E of 31.23x (PEG 2.83) but supported by expected EPS expansion to $12.14 from $8.62. Q2 2026 results confirm solid 6.6% YoY revenue growth ($25.31B) and 28% operating margins, with the $14.6B Caplyta acquisition integration on track. Key risks include Stelara biosimilar erosion, litigation overhang, and limited near-term upside given premium valuation, while strengths include 60+ years of dividend growth, ultra-low 0.235 beta, and disciplined capital return through buybacks.
Macro: Hawkish Fed regime: Polymarket prices 96% probability of no 2026 rate cuts, 86% probability of another Fed hike in 2026, and 62% probability of two or more hikes; US recession odds for 2026 fell to 8% (-7pp on the week). No imminent recession risk priced; healthcare demand (defensive, needs-driven) stays stable. Bitcoin rallied above $86K. Fed hiking environment is unusual but markets are dismissing recession risk—regime where defensive quality (like JNJ) outperforms.